EGFR and non-small cell lung carcinoma: However, the ORIENT-31 study confirmed that ICI combined with anti-angiogenic therapy and chemotherapy significantly improved PFS in EGFR-mutant non-squamous NSCLC patients who progressed after treatment with EGFR-TKIs [31].